Table 1.
Data related to evaluated studies
|
| ||||||||||||||
| Author | Design | Year | Country | Sample size PKP | Sample size DALK | Mean age in PKP | Mean age in DALK | Follow-up PKP (month) | Follow-up DALK (month) | PKP Sex Male | PKP Sex Female | DALK Sex Male | DALK Sex Female | Main value evaluated |
| Abdelaal et al[23] | Retrospective cohort | 2021 | Saudi Arabia | 15 | 21 | Graft Rejection | ||||||||
| Abu Eta et al[24] | Retrospective cohort | 2020 | Israel | 21 | 32 | High-IOP | ||||||||
| Akdemir et al[25] | Retrospective cohort | 2012 | Turkey | 30 | 30 | 28.07 | 29.67 | 12.58 | 12.58 | 16 | 14 | 14 | 16 | BCVA |
| Alzahrani et al[26] | Retrospective cohort | 2018 | UK | 21 | 16 | 30.14 | 32.56 | 13.95 | 14.87 | 14 | 7 | 11 | 5 | BCVA, CCT |
| Amayem et al[27] | Retrospective cohort | 2012 | Saudi Arabia | 30 | 47 | 26.5 | 24.3 | 24 | 24 | Refractive Cylinder, SE | ||||
| Bahar et al[28] | Retrospective cohort | 2008 | Canada | 20 | 17 | 42.2 | 32.5 | 53.2 | 17 | 11 | 9 | 11 | 6 | Endothelial Cell Count, Infection Rate, Graft Rejection, Topographic Cylinder |
| Cohen et al[29] | Retrospective cohort | 2010 | USA | 30 | 11 | 35.4 | 45.5 | 21.9 | 22.5 | 21 | 9 | 8 | 3 | Cataract Frequency, High-IOP, Graft Rejection, Refractive Cylinder, SE, BCVA |
| Donoso et al[30] | Retrospective cohort | 2015 | Chile | 49 | 90 | 31.7 | 28.3 | 48.6 | 36.8 | High-IOP, ECC, Infection Rate, Graft Rejection, Topographic and Refractive Cylinder, CCT | ||||
| Funnell et al[31] | Cohort | 2006 | UK | 20 | 20 | 32 | 28 | 12 | 12 | 14 | 6 | 11 | 9 | High-IOP, Graft Rejection, Graft Failure, Topographic Cylinder |
| Godefrooij et al[32] | Retrospective cohort | 2016 | Netherlands | 736 | 297 | 38.07 | 35.65 | 499 | 237 | 204 | 93 | BCVA | ||
| Hamdi et al[33] | Cross-sectional | 2017 | Egypt | 12 | 24 | 26.95 | 23.79 | 9 | 3 | 14 | 10 | Topographic and Refractive Cylinder, SE, BCVA | ||
| Huang et al[34] | Retrospective cohort | 2015 | China | 79 | 68 | 24.3 | 24.1 | 93.1 | 93.5 | 50 | 29 | 40 | 28 | Topographic and Refractive Cylinder, SE, BCVA |
| Jafarinasab et al[35] | Cross-sectional | 2011 | Iran | 45 | 23 | 29.8 | 27.2 | 31.4 | 29.2 | Topographic Cylinder, SE, BCVA | ||||
| Janiszewska-Bil et al[36] | Cohort | 2021 | Poland | 40 | 50 | 28.4 | 28.6 | 12 | 12 | 24 | 16 | 28 | 22 | High-IOP, ECC, Topographic Cylinder, CCT, BCVA |
| Javadi et al[37] | Randomized clinical trial | 2010 | Iran | 35 | 42 | 30.89 | 26.91 | 24.6 | 22 | 28 | 7 | 29 | 13 | Graft Rejection, Topographic Cylinder, CCT, SE, BCVA |
| Jones et al[38] | Retrospective cohort | 2009 | UK | 1917 | 455 | Graft Rejection, Graft Failure, SE, BCVA | ||||||||
| Kasbekar et al[39] | Cohort | 2014 | UK | 3124 | 1086 | 60 | 60 | Infection rate, Graft Rejection, Graft Failure | ||||||
| Khattak et al[40] | Retrospective cohort | 2018 | Saudi Arabia | 99 | 108 | 28.9 | 27.8 | 29.3 | 28.1 | 59 | 40 | 67 | 41 | High-IOP, ECC, Cataracts, Infection rate, Graft Rejection, Graft Failure, Topographic and Refractive Cylinder, SE, BCVA |
| Kim et al[41] | Retrospective cohort | 2011 | Korea | 38 | 19 | 26.2 | 25.3 | 51.7 | 22.6 | 25 | 13 | 17 | 2 | SE |
| Koytak et al [42] | Retrospective cohort | 2011 | Turkey | 39 | 44 | 36.24 | 34.54 | 24 | 24 | 24 | 15 | 26 | 18 | ECC, CCT |
| Kubaloglu et al [43] | Cohort | 2011 | Turkey | 24 | 20 | 30.2 | 25.6 | 6 | 6 | 112 | 95 | Topographic and Refractive Cylinder, SE, CCT, BCVA | ||
| Macintyre et al [44] | Retrospective cohort | 2014 | Australia | 42 | 31 | 32.3 | 29.2 | 53.7 | 51.8 | 22 | 20 | 19 | 12 | Cataracts, Graft Rejection, Graft Failure, Refractive Cylinder, BCVA |
| Motlagh et al [45] | Cross-sectional | 2012 | Iran | 57 | 49 | 35 | 30.3 | SE, BCVA | ||||||
| Oh et al [46] | Retrospective cohort | 2013 | Korea | 5 | 11 | 27.4 | 28 | 45 | 30 | 3 | 2 | 7 | 4 | ECC, Refractive and Topographic Cylinder, CCT, SE, BCVA |
| Pedrotti et al [47] | Retrospective cohort | 2016 | Italy | 16 | 16 | 34.1 | 35.9 | 7 | 9 | 7 | 9 | Graft Rejection, Graft Failure, Topographic and REfractive Cylinder, CCT, SE, BCVA | ||
| Sogutlu Sari et al [48] | Cohort | 2012 | Turkey | 75 | 99 | 28.44 | 27.59 | 25.53 | 21.54 | Graft Rejection, Refractive Cylinder, SE, BCVA | ||||
| Watson et al [49] | Retrospective cohort | 2004 | UK | 22 | 25 | 33.9 | 32.6 | 55 | 28 | 14 | 8 | 17 | 8 | Infection, Graft Rejection, Graft Failure, |
| Yüksel et al [50] | Clinical trial | 2017 | Turkey | 38 | 38 | 35.3 | 34.9 | 12 | 12 | 15 | 23 | 10 | 28 | High-IOP, Graft Rejection, Topographic Cylinder, SE, BCVA |
| Zhang et al [51] | Retrospective cohort | 2013 | China | 52 | 75 | 21.9 | 20.6 | 60.2 | 46.9 | 45 | 7 | 55 | 20 | High-IOP, Cataracts, Graft Rejection, Topographic Cylinder, SE |
| Ziaei et al [52] | Retrospective cohort | 2019 | New Zealand | 42 | 27 | 35 | 36.1 | 25 | 17 | 12 | 15 | CCT | ||